China Scraps Outpatient Prepayment in Public Hospitals by 2025: Healthcare Reform Shifts Financial Burden
The National Health Commission (NHC) will eliminate outpatient prepayment requirements across public medical institutions by...
Policy / Regulatory
China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled
China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...
Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications
Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...
Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics
The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...
China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control
China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...
China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation
The Pharmacopoeia of the People’s Republic of China (2025 Edition), released by the National Medical...
China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement
China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...
NMPA Updates Rules on Domestic Production of Imported Medical Devices
The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...
Driving Innovation in Traditional Chinese Medicine: A Policy-Backed Renaissance
In Depth Analysis of Policy News in the Pharmaceutical Sector: A Comprehensive Guide to the...
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...
NMPA Seeks Public Input on Drug Trial Data Protection Measures
On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...
CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings
The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...
HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...
China Issues Guidelines for Informatization of Compact County-level Medical Communities
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...
China’s NHSA Issues Guidelines for Neurological Medical Services Pricing
China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...
Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown
In a momentous address at the Third Session of the 14th National People’s Congress on...
CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D
China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...